American Renal Associates Holdings Inc. (NYSE:ARA) shares traded down 2% during mid-day trading on Thursday . The stock traded as low as $23.09 and last traded at $23.30, with a volume of 184,050 shares changing hands. The stock had previously closed at $23.78.

Several research analysts have issued reports on the company. Zacks Investment Research raised American Renal Associates Holdings from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a report on Thursday. SunTrust Banks Inc. began coverage on American Renal Associates Holdings in a report on Monday, May 16th. They issued a “buy” rating and a $34.00 price target on the stock. Wells Fargo & Co. began coverage on shares of American Renal Associates Holdings in a research note on Monday, May 16th. They set an “outperform” rating on the stock. Leerink Swann reissued an “outperform” rating on shares of American Renal Associates Holdings in a research note on Monday, May 16th. Finally, Goldman Sachs Group Inc. began coverage on shares of American Renal Associates Holdings in a research note on Monday, May 16th. They set a “neutral” rating and a $30.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $31.20.

The stock’s market cap is $709.35 million. The stock’s 50 day moving average is $0.00 and its 200 day moving average is $0.00.

American Renal Associates Holdings (NYSE:ARA) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.75) EPS for the quarter. The firm had revenue of $185.60 million for the quarter, compared to analyst estimates of $161.50 million. On average, analysts anticipate that American Renal Associates Holdings Inc. will post $0.88 earnings per share for the current year.

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.